Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NUCALA ® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term）

NCT03557060 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03557060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03557060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NUCALA ® Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term）
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
June 25, 2018
Completion date
July 30, 2025
Enrollment
4,115 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

churg-strauss syndrome, eosinophilic granulomatosis with polyangiitis